ATR:NYE-AptarGroup Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 175.5

Change

-0.20 (-0.11)%

Market Cap

USD 11.68B

Volume

0.17M

Analyst Target

USD 125.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, and aerosol valves to the digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois. Address: 265 Exchange Drive, Crystal Lake, IL, United States, 60014

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-0.05 (-0.02%)

USD 66.85B
ALC Alcon AG

+0.60 (+0.69%)

USD 43.35B
RMD ResMed Inc

-11.77 (-4.76%)

USD 35.86B
BAX Baxter International Inc

-1.20 (-3.55%)

USD 17.26B
AVTR Avantor Inc

-0.21 (-0.96%)

USD 14.69B
TFX Teleflex Incorporated

-1.60 (-0.82%)

USD 9.08B
BLCO Bausch + Lomb Corp

+0.22 (+1.13%)

USD 6.88B
STVN Stevanato Group SpA

-0.19 (-0.92%)

USD 5.19B
WRBY Warby Parker Inc

-0.11 (-0.52%)

USD 2.03B
INFU InfuSystems Holdings Inc

-0.58 (-6.10%)

USD 0.17B

ETFs Containing ATR

NBSM Neuberger Berman ETF Trus.. 2.85 % 0.00 %

-0.09 (-0.33%)

USD 0.20B
XMLV Invesco S&P MidCap Low Vo.. 1.78 % 0.25 %

-0.23 (-0.33%)

USD 0.85B
TQSM:CA TD Q U.S. Small-Mid-Cap E.. 1.77 % 0.00 %

-0.03 (-0.33%)

CAD 0.19B
FCUL:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.97% 89% A- 90% A-
Dividend Return 1.39% 70% C- 26% F
Total Return 43.36% 89% A- 90% A-
Trailing 12 Months  
Capital Gain 37.42% 84% B 82% B
Dividend Return 1.35% 60% D- 16% F
Total Return 38.77% 84% B 82% B
Trailing 5 Years  
Capital Gain 59.60% 75% C 74% C
Dividend Return 7.06% 71% C- 19% F
Total Return 66.66% 81% B- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.16% 53% F 56% F
Dividend Return 7.33% 58% F 53% F
Total Return 1.17% 56% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 21.38% 74% C 52% F
Risk Adjusted Return 34.29% 89% A- 51% F
Market Capitalization 11.68B 64% D 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector